About Singulex

Singulex manages risks by answering critical health questions about disease and therapeutic intervention with our advanced immunodiagnostic products.

Singulex, Inc. has pioneered technology that can quantitatively detect single molecules, such as proteins and metabolites, in complex biological samples. Our technology extends the dynamic range of any immunoassay by orders of magnitude, allowing drug developers to use biomarkers to measure drug efficacy, safety and disease progression.

We have leveraged this unique technology to develop the Erenna™ Technology Access Program (ETAP) that allows select partners to access our sample analysis and assay development services as well as our world-class Erenna Immunoassay System.

Singulex’s core competencies focus on advancing industry-leading sample analysis and assay development services. Our team of scientists in St. Louis and Silicon Valley are experts in the field of immunoassay development.

In addition, our state-of-the-art facilities ensure that our immunoassay consumables are manufactured to the highest standards. Our corporate priority is to continue to maintain and develop a strong intellectual property portfolio covering all aspects of our technology and assays.